Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd-Rüdiger Balda
Michael Hertl

Showing results (21-30 of 245) with videos related to

Pageof 25
Sort By:
Frontiers in Immunology|October 20, 2022
Detection of anti-desmoglein antibodies in oral lichen planus: What do we know so farDario Didona, Michael Hertl
The Journal of Investigative Dermatology|January 15, 2011
Clinical and molecular characterization of autoimmune bullous diseasesMichael Hertl, Detlef Zillikens
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 18, 2021
Michael Hertl, Julia Welzel
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 30, 2011
Autoimmune bullous skin diseases. Part 1: Clinical manifestationsAndrea Kneisel, Michael Hertl
Wiener Medizinische Wochenschrift (1946)|August 1, 2014
[Bullous pemphigoid: diagnosis and therapy]Andrea Kneisel, Michael Hertl
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 29, 2020
Tilo Biedermann, Michael Hertl
Current Opinion in Pharmacology|February 16, 2019
Pharmacological advances in pemphigoidRoberto Maglie, Michael Hertl
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|April 1, 2021
[Paraneoplastic skin syndromes]Amir S Yazdi, Michael Hertl
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 11, 2020
Isaak Effendy, Uwe Gieler, Michael Hertl
Archives of Dermatology|July 20, 2011
Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?Michael Hertl, Philippe Bernard, Luca Borradori
Pageof 25

Showing results (21-30 of 245) with videos related to

Sort By:
Pageof 25
Frontiers in Immunology|October 20, 2022
Detection of anti-desmoglein antibodies in oral lichen planus: What do we know so farDario Didona, Michael Hertl
The Journal of Investigative Dermatology|January 15, 2011
Clinical and molecular characterization of autoimmune bullous diseasesMichael Hertl, Detlef Zillikens
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 18, 2021
Michael Hertl, Julia Welzel
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 30, 2011
Autoimmune bullous skin diseases. Part 1: Clinical manifestationsAndrea Kneisel, Michael Hertl
Wiener Medizinische Wochenschrift (1946)|August 1, 2014
[Bullous pemphigoid: diagnosis and therapy]Andrea Kneisel, Michael Hertl
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 29, 2020
Tilo Biedermann, Michael Hertl
Current Opinion in Pharmacology|February 16, 2019
Pharmacological advances in pemphigoidRoberto Maglie, Michael Hertl
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|April 1, 2021
[Paraneoplastic skin syndromes]Amir S Yazdi, Michael Hertl
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 11, 2020
Isaak Effendy, Uwe Gieler, Michael Hertl
Archives of Dermatology|July 20, 2011
Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?Michael Hertl, Philippe Bernard, Luca Borradori
Pageof 25